- Jan 7, 2016
adjunct means along with existing treatment protocols, isn’t it?An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. Twitter/@DRDO_India
The Drugs Controller General of India (DCGI) has granted permission for emergency use of anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) developed by Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories (DRL),Hyderabad.
In a release issued on Saturday, the Ministry of Defence said that as per the order, emergency use of this drug as adjunct therapy in moderate to severe COVID-19 patients is permitted. It added that being a generic molecule and analogue of glucose, it can be easily produced and made available in plenty in the country.
|Thread starter||Similar threads||Forum||Replies||Date|
|W||Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients||Economy & Infrastructure||0|
|W||US approves $450 million F-16 fleet sustainment programme to Pakistan||Pakistan||8|
|US approves $1.1 billion arms package for Taiwan, angering China||Indo Pacific & East Asia||0|
|W||MoD approves 107 Major Line Replacement Units/Sub-systems for Indigenisation||Defence & Strategy||0|